Zymeworks Inc.

Zymeworks Inc. delivers clinical-stage biotech solutions with multi‑specific antibody and conjugate platforms targeting cancer and AIID. Its leading bispecific zanidatamab is in Phase 3 trials, supported by partners such as Merck, Lilly and BeiGene.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 263
HQ: Middletown

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
ZYME	Zymeworks Inc. Cap: 1.8B	EQUITY	NYQ	USD	CA98985W1023	Active	📈